Search
Search results
374 results found
USF Parkinson's Disease and Movement Disorders Center
Parkinson’s disease, clinical trials, treatment, evaluation, Robert Hauser, Botox, Movement Disorder, tremor, cervical dystonia, blepharospasm, hemifacial spasm
Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study. 2022 Mar 14;
Comella, C, RA Hauser, SH Isaacson, D Truong, O Oguh, J Hui, ES Molho, et al. 2022. “Efficacy and Safety of Two IncobotulinumtoxinA Injection Intervals in Cervical Dystonia Patients With Inadequate Benefit from Standard Injection Intervals of Botulinum Toxin: Phase 4, Open-Label, Randomized, Noninferiority Study. 2022 Mar 14;”. Clin Park Relat Disord.
Trial of Prasinezumab in Early-Stage Parkinson's Disease. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. PMID: 35921451
Pagano, G, RA Hauser, KI Taylor, J Anzures-Cabrera, M Marchesi, T Simuni, K Marek, RB Postuma, N Pavese, and . 2022. “Trial of Prasinezumab in Early-Stage Parkinson’s Disease. 2022 Aug 4;387(5):421-432. Doi: 10.1056/NEJMoa2202867. PMID: 35921451”. N Engl J Med.
IPX203 versus immediate-release carbidopa-levodopa for the treatment of motor fluctuations in Parkinson’s Disease: The RISE-PD Randomized Clinical Trial of Trial. 2023 Oct 1;80(10):1062-1069. doi: 10.1001/jamaneurol.2023.2679. PMID: 37578800
Hauser, RA, AJ Espay, AL Ellenbogen, HH Fernandez, SH Isaacson, PA LeWitt, WG Ondo, et al. 2023. “IPX203 versus Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson’s Disease: The RISE-PD Randomized Clinical Trial of Trial. 2023 Oct 1;80(10):1062-1069. Doi: 10.1001/Jamaneurol.2023.2679. PMID: 37578800”. JAMA Neurol.
The Clinician's Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia.
Trosch, RM, CL Comella, RA Hauser, SN Caroff, WG Ondo, AC Shillington, BJ LaChappelle, CU Correll, and JH Friedman. 2024. “The Clinician’s Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia.”. J Clin Psychiatry. 2024 Jan 24;85(1):23m14886. Doi: 10.4088/JCP.23m14886. PMID: 38270545.
Intrinsic auricular muscle zone stimulation for Parkinson disease: The EARSTIM-PD Phase II multi-center pilot study results
Fernandez, HH, EA Macklin, RA Hauser, KL Chou, YO Cakmak, B Ozsoy, S Fahn, and Parkinson Study Group. 2024. “Intrinsic Auricular Muscle Zone Stimulation for Parkinson Disease: The EARSTIM-PD Phase II Multi-Center Pilot Study Results”. . Parkinsonism Relat Disord. 2024 Apr;121:105959. Doi: 10.1016/J.Parkreldis.2023.105959. Epub 2023 Dec 27. PMID: 38246833.
Current use of neurotoxins for alleviating symptoms of cervical dystonia.
Aradi, S, and R Hauser. 2024. “Current Use of Neurotoxins for Alleviating Symptoms of Cervical Dystonia.”. Expert Review of Neurotherapeutics. June 2024 DOI: 10.1080/14737175.2024.2368638.
Pimavanserin treatment for Parkinson's disease psychosis in clinical practice. Parkinsons Dis 2021:2603641. doi: 10.1155/2021/2603641.
Dashtipour, K, F Gupta, RA Hauser, CA Krunapuzha, and JC Morgan. 2021. “Pimavanserin Treatment for Parkinson’s Disease Psychosis in Clinical Practice. Parkinsons Dis 2021:2603641. Doi: 10.1155/2021/2603641.”. Parkinsons Dis.
Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease. Front Neurol. 2021 Mar 26;12:645706. doi: 10.3389/fneur.2021.645706. eCollection 2021.PMID: 33841311.
Hauser, RA, RR Walsh, R Pahwa, D Chernick, and AE Formella. 2021. “Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson’s Disease. Front Neurol. 2021 Mar 26;12:645706. Doi: 10.3389/Fneur.2021.645706. ECollection 2021.PMID: 33841311.”. Front Neurol.